Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations
- PMID: 11687599
- PMCID: PMC1906963
- DOI: 10.1016/S1525-1578(10)60667-8
Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations
Abstract
The incidence of melanoma is increasing rapidly in western countries. Genetic predisposition in familial and in some sporadic melanomas has been associated with the presence of INK4A gene mutations. To better define the risk for developing sporadic melanoma based on genetic and environmental interactions, large groups of cases need to be studied. Mutational analysis of genes lacking hot spots for sequence variations is time consuming and expensive. In this study we present the application of denaturing high performance liquid chromatography (DHPLC) for screening of mutations. Exons 1alpha, 2, and 3 were amplified from 129 samples and 13 known mutants, yielding 347 products that were examined at different temperatures. Forty-two of these amplicons showed a distinct non-wild-type profile on the chromatogram. Independent sequencing analysis confirmed 16 different nucleotide variations in Leu32Pro; Ile49Thr; 88 del G; Gln50Arg; Arg24Pro; Met53Ile; Met53Thr; Arg58stop; Pro81Leu; Asp84Ala; Arg80stop; Gly101Trp; Val106Val; Ala148Thr; and in positions (-2) in intron 1 (C --> T); and in the 3' UTR, nucleotide 500 (C --> G). No false negatives or false positives were obtained by DHPLC in samples with mutations or polymorphisms. We conclude that the DHPLC is a fast, sensitive, cost-efficient, and reliable method for the scanning of INK4A somatic or germline mutations and polymorphisms of large number of samples.
Figures


Similar articles
-
Evaluation of denaturing high performance liquid chromatography for the mutational analysis of the MEN1 gene.J Mol Endocrinol. 2006 Apr;36(2):369-76. doi: 10.1677/jme.1.01903. J Mol Endocrinol. 2006. PMID: 16595707
-
Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2845-51. Invest Ophthalmol Vis Sci. 2002. PMID: 12202501
-
Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations.Nucleic Acids Res. 1998 Mar 15;26(6):1396-400. doi: 10.1093/nar/26.6.1396. Nucleic Acids Res. 1998. PMID: 9490783 Free PMC article.
-
In-depth mutation and SNP discovery using DHPLC gene scanning.Curr Opin Drug Discov Devel. 2003 Mar;6(2):237-52. Curr Opin Drug Discov Devel. 2003. PMID: 12669460 Review.
-
The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes.Methods Mol Biol. 2010;653:133-45. doi: 10.1007/978-1-60761-759-4_8. Methods Mol Biol. 2010. PMID: 20721741 Review.
Cited by
-
Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.BMC Med Genet. 2007 Mar 8;8:10. doi: 10.1186/1471-2350-8-10. BMC Med Genet. 2007. PMID: 17346338 Free PMC article.
-
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.Eur J Hum Genet. 2011 Apr;19(4):472-8. doi: 10.1038/ejhg.2010.198. Epub 2010 Dec 8. Eur J Hum Genet. 2011. PMID: 21150883 Free PMC article.
-
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).Eur J Cancer. 2008 Jun;44(9):1269-74. doi: 10.1016/j.ejca.2008.03.005. Epub 2008 Apr 3. Eur J Cancer. 2008. PMID: 18394881 Free PMC article.
-
Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study.Cancer Epidemiol Biomarkers Prev. 2021 Dec;30(12):2309-2316. doi: 10.1158/1055-9965.EPI-21-0686. Epub 2021 Oct 4. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 34607836 Free PMC article.
-
A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.J Invest Dermatol. 2011 Feb;131(2):480-6. doi: 10.1038/jid.2010.331. Epub 2010 Nov 18. J Invest Dermatol. 2011. PMID: 21085193 Free PMC article.
References
-
- Rigel DS, Carucci JA: Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 2000, 50:215–236; 237–240 - PubMed
-
- Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U: Trends in mortality from malignant melanoma in Sweden, 1970–1996. Cancer 2000, 89:348-355 - PubMed
-
- Hara H, Walsh N, Yamada K, Jimbow K: High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid, as a prognostic marker for malignant melanoma. J Invest Dermatol 1994, 102:501-505 - PubMed
-
- DiFronzo LA, Wanek LA, Elashoff R, Morton DL: Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 1999, 6:705-711 - PubMed
-
- Serraino D, Fratino L, Gianni W, Campisi C, Pietropaolo M, Trimarco G, Marigliano V: Epidemiological aspects of cutaneous malignant melanoma. Oncol Rep 1998, 5:905-909 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources